An Open-label, Multicentre, Nonrandomized, Dose-escalating Phase I/II Study, With a Randomized Phase II Part, to Investigate the Safety and Tolerability of RO5072759 Given as Monotherapy in Patients With CD20+ Malignant Disease

Trial Profile

An Open-label, Multicentre, Nonrandomized, Dose-escalating Phase I/II Study, With a Randomized Phase II Part, to Investigate the Safety and Tolerability of RO5072759 Given as Monotherapy in Patients With CD20+ Malignant Disease

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Oct 2016

At a glance

  • Drugs Obinutuzumab (Primary)
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GAUGUIN
  • Sponsors Roche
  • Most Recent Events

    • 13 Jan 2014 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 08 Jul 2013 Results of the randomised part of the study (n=40) published in the Journal of Clinical Oncology.
    • 08 Jul 2013 Results of the randomised part of the study (n=40) published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top